Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million
Herantis Pharma Plc
Company release 12 March 2019, 5:00 pm
Not for publication or distribution, directly or indirectly, in or into Australia, South Africa, Hong Kong, Japan, Canada or the United States of America or in any other jurisdiction in which publishing or distributing would be prohibited by applicable law
The Board of Directors of Herantis Pharma Plc (“Herantis” or “Company”) has today decided on a directed share issue of 1.111.982 new shares in aggregate, at a per-share subscription price of EUR 5.20, to certain institutional investors and a limited number of investors other than qualified investors as well as to certain directors of the Company. The share issue was based on an authorization of the Company’s Extraordinary Meeting of Shareholders convening on 12 March 2019.
The share capital will not be increased. Instead, the entire subscription price of EUR 5,782,306.40 will be recorded in the invested unrestricted equity reserve of the Company. As a result of the share subscriptions, the number of shares in Herantis Pharma Plc will increase to 6,030,287 shares.
The proceeds of the offering will primarily be used towards financing the preparations for the Phase 2 and Phase 3 clinical studies of CDNF and Lymfactin, for the preclinical development of a non-invasive CDNF, for strengthening the Company’s capital structure, and for other purposes decided by the Board of Directors of Herantis.
“The additional support of long-term strategic institutional investors highlights the potential of our two development programs. It also enables us to achieve the near-term milestones that can further validate them”, said Pekka Simula, CEO of Herantis. “The financing provides us with more stability to execute and drive value for our investors as we advance our clinical trials in Parkinson’s disease and secondary lymphedema.”
“With a better understanding for disease mechanisms, neurology including Parkinson’s disease is now more ripe for not only symptomatic treatment but truly disease modifying therapies”, said Mattias Häggblom, portfolio manager for Medica, Swedbank Robur’s global healthcare fund. “We find Herantis’ early data around CDNF very encouraging and look forward to support further clinical development to potentially bring this new treatment option to patients.”
Swedbank Robur was the lead investor in the directed share issue.
The issued new shares will be registered in the Trade Register on or about 22 March 2019, as of which date the new shares will carry shareholder rights. The issued new shares will be traded on Nasdaq Helsinki Ltd’s First North marketplace together with the old shares as of about 25 March 2019.
UB Securities Ltd acted as the sole lead manager of the share issue.
Share information of the Herantis Pharma Plc share after the registration of the new shares:
Trading Code: HRTIS
ISIN code: FI4000087861
List: First North Helsinki
Industry: Health Care
Number of Shares: 6,030,287
Share Capital: 80,000.00 euro
Herantis Pharma Plc., Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.
Not for publication or distribution, directly or indirectly, in or into Australia, South Africa, Hong Kong, Japan, Canada or the United States of America or in any other jurisdiction in which publishing or distributing would be prohibited by applicable law.
This release is not a prospectus and not an offer relating to securities. No offer will be made in any such jurisdiction in which the offer or participation therein would be unlawful or would require the preparation of a prospectus, registration or any other similar action. The sole lead manager is acting exclusively for the Company and no one else connected to the share issue. The sole lead manager will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the contents of this release or the transaction pursuant to this release.
This release is directed only to (A) persons who are outside the United States of America; (B) (i) persons who are resident in a Member State of the European Economic Area (other than Finland) and are a qualified investor (within the meaning of Article 2(1)(e) of Directive 2003/71/EC and any relevant implementing measure in each Member State of the European Economic Area); or (ii) persons who are resident in Finland and are a qualified investor (within the meaning of Chapter 3, Section 5 of the Finnish Securities Markets Act (746/2012, as amended, in Finnish: kokenut sijoittaja); and (C) as regards Great Britain, (i) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); (ii) high net worth entities; and (iii) and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as “Relevant Persons”). Any shares offered in the share issue or requests, offers or agreements relating to the subscription for, purchase of or any other acquisition of such shares are intended to be made available to Relevant Persons only. No one who is not a Relevant Person shall act on the basis of this release.
This release does not constitute an offer for sale of securities in the United States. The shares may not be offered or sold within the United States absent of registration or an exemption under the U.S. Securities Act 1933 (as amended). The Company has not registered and it does not intend to register, any portion of the offering in the United States, and it does not intend to conduct a public offering in the United States.
This release contains forward-looking statements. These forward-looking statements are not based on historical facts, but are statements about future expectations. Statements included in this release which contain expressions “considers”, “aims”, “anticipates”, “assumes”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “should”, and other similar expressions related to the Company or the possible share issue are examples of such forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. Forward-looking statements contain information about future results, plans or expectations regarding the Company’s business operations, including its strategy and growth plans and profitability, and the general economic situation. These forward-looking statements are based on current plans, estimates, prospects and expectations. They are based on certain currently valid expectations that may however turn out to be wrong. These forward-looking statements are based on assumptions and they contain several risks and uncertainties. Investors should not rely on these forward-looking statements. Several factors may result in a material deviation of the Company’s actual business outcome or financial standing from the business outcome or financial standing that is indicated or referred to in forward-looking statements. The absence or occurrence of the aforementioned factors may cause a substantial deviation of the Company’s actual business outcome or financial standing from what is directly or indirectly presented or described in the sections, which include forward-looking statements. Because of risks, uncertainties, assumptions and other factors, events described in forward-looking statements may not necessarily occur. Therefore, the accuracy and completeness or the occurrence of the predicted events of the forward-looking statements presented in this release cannot be guaranteed.